Another Fine Mess For AZ As ‘Outdated’ Vaccine Data Queried
Newer Data Gives Lower Efficacy Score
Executive Summary
A new “unforced error” from AstraZeneca in reporting clinical data is keeping its COVID-19 vaccine in the headlines for the wrong reasons.
You may also be interested in...
After Vaccine Results Row, AZ Recalculates And Looks To Move On
AstraZeneca will want to move on from the incident, but is certain to face extra scrutiny at the US FDA.
AZ COVID-19 Vaccine Scores 79% In Pivotal US Trial – Any Hope For A Fresh Start?
The US FDA will now have the full efficacy data that it wanted from AstraZeneca, but the company still has to deal with concerns over safety and global supply issues.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.